Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Wan, Jinkai; Xing, Shenghui; Ding, Longfei; Wang, Yongheng; Zhu, Dandan; Rong, Bowen; Wang, Siqing; Chen, Kun; He, Chenxi; Yuan, Songhua; Qiu, Chengli; Zhao, Chen; Gao, Zhangzhao; Jiao, Jingyu; Zhang, Xiaoyan; Wang, Xiangxi; Wang, Haibin; Lu, Yuele; Xu, Jianqing; Lan, Fei

doi:10.2139/ssrn.3613271

Cited by 40 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most direct method for the enumeration of antigen‐specific B cells involves the binding of a fluorescently labelled antigen. The staining of PBMCs derived from patients with acute disease or convalescent patients using fluorochrome‐labelled RBD or S trimer showed the presence of 0.075–1.86% of antigen‐specific Bmem cells in the total B‐cell population 4,5,11,12,30–32 . The percentage of antigen‐positive cells varied widely depending on the number of days after symptom onset as well as the individual characteristics of donors.…”

Section: Discussionmentioning

confidence: 99%

“…Information on SARS‐CoV‐2‐specific B‐cell memory is considerably limited. Bmem cells obtained from recently recovered patients have been actively used for the isolation and sequencing of immunoglobulin (Ig) genes for the subsequent generation of SARS‐CoV‐2‐neutralising antibodies 4,5,11,12 . However, Bmem cells per se , and their generation and action dynamics are yet to be studied extensively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19

et al. 2021

View full text Add to dashboard Cite

Objectives To predict the spread of coronavirus disease (COVID‐19), information regarding the immunological memory for disease‐specific antigens is necessary. The possibility of reinfection, as well as the efficacy of vaccines for COVID‐19 that are currently under development, will largely depend on the quality and longevity of immunological memory in patients. To elucidate the process of humoral immunity development, we analysed the generation of plasmablasts and virus receptor‐binding domain (RBD)‐specific memory B (Bmem) cells in patients during the acute phase of COVID‐19. Methods The frequencies of RBD‐binding plasmablasts and RBD‐specific antibody‐secreting cells (ASCs) in the peripheral blood samples collected from patients with COVID‐19 were measured using flow cytometry and the ELISpot assay. Results The acute phase of COVID‐19 was characterised by the transient appearance of total as well as RBD‐binding plasmablasts. ELISpot analysis indicated that most patients exhibited a spontaneous secretion of RBD‐specific ASCs in the circulation with good correlation between the IgG and IgM subsets. IL‐21/CD40L stimulation of purified B cells induced the activation and proliferation of Bmem cells, which led to the generation of plasmablast phenotypic cells as well as RBD‐specific ASCs. No correlation was observed between the frequency of Bmem cell‐derived and spontaneous ASCs, suggesting that the two types of ASCs were weakly associated with each other. Conclusion Our findings reveal that SARS‐CoV‐2‐specific Bmem cells are generated during the acute phase of COVID‐19. These findings can serve as a basis for further studies on the longevity of SARS‐CoV‐2‐specific B‐cell memory.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Andreano et al from Italy found 17 neutralizing antibodies from 7 COVID-19 patients ( Andreano et al, 2020 ). Wan, Xing et al from China isolated 8 antibodies which can be used as paired antibodies to potently block infection of authentic virus with IC 50 of 0.45 nM ( Wan et al, 2020 ).…”

Section: Potential Ab Drugs Derived From Convalescent Patients and Gementioning

confidence: 99%

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Shi

Liang

et al. 2021

Stem Cell Research

View full text Add to dashboard Cite

show abstract

“…The prospect of combining monoclonal antibodies (mAbs) 553-15 and S309 with other antibodies in a cocktail is particularly attractive because these mAbs demonstrate a potent synergistic neutralizing effect with many of the other antibodies. 56,57 Moreover, mAb CR3022 might be combined with mAb COV21, C105, or B38 in a cocktail because CR3022 does not appear to compete with these three antibodies for binding to the SARS-CoV-2 S glycoprotein, and therefore might offer synergistic neutralizing effects. 58,59 Similarly, the potent NTD-binding nAb 4A8 might also be considered in a cocktail with RBD-binding antibodies because 4A8 binding to the NTD leaves the RBD region of the S glycoprotein free for co-binding antibodies that might offer additive neutralizing effects.…”

Section: Antibody Treatmentsmentioning

confidence: 99%

Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak

et al. 2021

View full text Add to dashboard Cite

An outbreak of the coronavirus disease 2019 (COVID-19) caused by an infection of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, in December 2019. This new virus belongs to the group of enveloped RNA beta-coronaviruses. Symptoms may differ in various infected persons, but major presentations include dry cough, nasal congestion, shortness of breath, fever, and general malaise. The disease appears to be more severe in patients above the age of 60 years and those with underlying conditions such as diabetes, cancer, cardiovascular diseases, chronic respiratory disease, and hypertension. There is still no approved vaccine against COVID-19, but more than a hundred are at different stages of development. It is known that the development of new drugs takes a relatively long time, so several known and already-approved drugs are being repurposed for the treatment of this disease. In this review, we explore the therapeutic and vaccine options that are available for COVID-19 6 months after its outbreak. Most noteworthy among the therapeutic options are dexamethasone, remdesivir, Avigan (favipiravir) and convalescent plasma.

show abstract

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Cited by 40 publications

References 0 publications

Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19

Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak

Contact Info

Product

Resources

About